Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials
about
Recent advances in understanding apicomplexan parasitesPlasmodium falciparum Secretome in Erythrocyte and BeyondThe malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugsAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkNext-generation antimicrobials: from chemical biology to first-in-class drugsOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesThe interplay between drug resistance and fitness in malaria parasitesUsing genetic methods to define the targets of compounds with antimalarial activityAntimalarial drug discovery - approaches and progress towards new medicines.Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of ActionA triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malariaOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondMutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone AntimalarialsBiochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseBiochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active CompoundsEvidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria ParasitesNa+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparumPyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitorA high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytesA lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparumThe Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic ScreensDiverse chemotypes disrupt ion homeostasis in the Malaria parasite.(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.Spiroindolone KAE609 for falciparum and vivax malaria.A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteerAntimalarial compounds in Phase II clinical development.Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box.Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.Antiparasitic chemotherapy: from genomes to mechanisms.Utilizing diversity-oriented synthesis in antimicrobial drug discovery.A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.Synthetic RNA-protein modules integrated with native translation mechanisms to control gene expression in malaria parasitesMaduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050.Ca(2+) monitoring in Plasmodium falciparum using the yellow cameleon-Nano biosensor.Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivoPhylogenetic profiles of all membrane transport proteins of the malaria parasite highlight new drug targetsMembrane transport in the malaria parasite and its host erythrocyte.
P2860
Q26747055-BF97868A-748F-4364-9324-7D94F1EEB1BFQ26765856-5C637E53-F1F2-44F2-A02F-6BBE4CB04B93Q26781634-5AA094D7-CB85-4B3B-A51A-807E60A79054Q26799713-31B69FFD-37FB-4CDD-A937-5B363CF10B7EQ26799749-FCC03D71-A139-471D-92F9-8F19DFD74F87Q26883657-259CFE52-17A4-4BC5-813D-6909B9617D69Q26998596-EDF5BEC4-00E2-40B1-B58C-2C3AA151FA4AQ27014788-DFF7AA46-E0B8-4754-B79A-634392E5C2D2Q27693245-8DCD1637-5842-4344-AB59-A358A7EBD125Q27702304-33060A71-C779-47F5-8A36-43F23FD9C5FDQ27728080-19084E95-4FA9-44E0-9D94-D271AD73AFFDQ27826351-B4F18521-5050-4973-9E22-B24A75C7E475Q27861952-8C4B3F33-E65C-4C9D-B0B5-84DD6DD9D31DQ28468285-907D3512-3123-4032-A9A6-16C3D614AEBCQ28550478-1CDD6DC4-BF08-4575-9D2E-1F9A1FE4CBB1Q28551519-C4E50463-06CC-4262-A0DC-415AD9EE9CB9Q28552457-54355ED7-BFEC-4631-AC6F-E851FF667216Q28649962-6DE4375C-9DDB-4080-B675-2F07C684C45EQ28830547-177450D1-6339-4B74-BE79-5B6AA9C0BB70Q28831140-601530D6-CBFC-4053-BA47-4936FC90680DQ30042958-49186954-F586-4777-9CBD-2E06F28C46B2Q30042965-A3E09DB1-1759-4540-9391-C57C6E0A7F12Q30487225-CB64ADEA-CD09-44A4-9C84-A70B2AEB689BQ30610467-EB63CF3E-51A9-4E28-8D7C-6931751DE71BQ34085717-CC0F0636-220F-4E27-AD10-EC479164A52DQ34298776-34D35F31-6254-48D9-B7BD-E8DC7A58DAA7Q34456807-F4959918-E58A-488C-937B-0670342577FFQ35046030-FFCEBD46-DD45-403A-92CF-68C91135B0B8Q35105913-49CBF56F-2725-4077-A427-CCA6EC375586Q35238319-F874A426-0E54-48AD-B499-409CAA947BE0Q35510383-F565E286-5F43-4B26-86E3-D7405B33E8ADQ36365291-733CDAC2-8111-49BA-90FA-87DE862BB961Q36637403-174DBBAA-A29B-4E2A-B019-99F5741C215FQ36644774-3F816374-ABAB-4459-B903-00B01556306EQ36719348-ECB85517-BECF-41E7-A4B1-184A206757C7Q37358648-9105340B-8B6D-4736-99B6-8CE89657A52CQ37613014-9CE92357-7C57-4D9F-AF1D-CBBCB8FDCEF0Q37643652-D439D2A4-C701-4CF2-ADFA-853456016386Q37698115-96B0243B-D5D3-4572-920C-3F72873386ACQ38170172-7661E771-9C6A-4F7D-BBA8-0422ED65A2D1
P2860
Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@ast
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@en
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@nl
type
label
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@ast
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@en
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@nl
prefLabel
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@ast
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@en
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Na(+) regulation in the malari ...... he spiroindolone antimalarials
@en
P2093
Case W McNamara
Richard J W Allen
Thierry T Diagana
P2860
P304
P3181
P356
10.1016/J.CHOM.2012.12.006
P407
P5008
P577
2013-02-01T00:00:00Z